Developing therapies for type 1 diabetes

Diamyd® and Remygen® are drugs in clinical development phase,
aimed to preserve and restore the body's insulin production.

 

Our pipeline for autoimmune diabetes is potentially game changing. Focusing on safe and specific interventions that have the promise to realize the true value of preemptive medicine. Spearheaded by Diamyd®, an antigen-specific immunotherapy for individuals carrying a common risk gene (haplotype DR3-DQ2”), provides us with the opportunity to address up to 40 % of the millions of individuals at risk or diagnosed with autoimmune diabetes in the world.

Ulf Hannelius
President and CEO, Diamyd Medical AB

ABOUT DIAMYD MEDICAL

Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development.

We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®.

Diamyd® and Remygen® are evaluated in ongoing clinical studies. The therapies target the underlying causes of diabetes, dysfunction and loss of the pancreas's insulin-producing cells.

Diamyd Medical’s shares are traded on Nasdaq First North Growth Market, ticker DMYD B.

 

ORGANISATION

Internal core competences constitute Diamyd Medical's core employees in collaboration with a global network of clinics, researchers and production units. Further expertise, including analysis- and laboratory services are contracted as needed during specific project phases. The model is based on long-term collaborations and cost efficiency.

Order GAD for preclinical research

ORDER

Annual Report

  November 29, 2022
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research